BMC Gastroenterology最新文献

{"title":"A chitinase-3-like protein-1-based nomogram for identification of significant liver fibrosis in the general population.","authors":"Piaopiao Jin, Nan Li, Chenbing Liu, Di Sheng, Lihong Qiu, Chenzhao Zhao, Zhong Liu","doi":"10.1186/s12876-025-04277-0","DOIUrl":"10.1186/s12876-025-04277-0","url":null,"abstract":"","PeriodicalId":9129,"journal":{"name":"BMC Gastroenterology","volume":"25 1","pages":"688"},"PeriodicalIF":2.5,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12482045/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145190900","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Therapeutic regimen of Crohn's disease: effect of Infliximab combined with mesalazine on intestinal flora and inflammatory indexes in patients.","authors":"Xiaoxia Xiang, Zhenghua Hu, Siyuan Dong, Bo Qi, Angyan Li, Liping Ji","doi":"10.1186/s12876-025-04236-9","DOIUrl":"10.1186/s12876-025-04236-9","url":null,"abstract":"","PeriodicalId":9129,"journal":{"name":"BMC Gastroenterology","volume":"25 1","pages":"687"},"PeriodicalIF":2.5,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12482166/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145191248","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Circular RNA profiling and functional analysis implicate circ-ANKRD36C as a potential prognostic biomarker in gastric cancer.","authors":"Rongpeng Chen, Tianxing Ji, Yuanqing Chu, Feng Xiao, Zhicheng Feng, Guoqiang Wang","doi":"10.1186/s12876-025-04287-y","DOIUrl":"10.1186/s12876-025-04287-y","url":null,"abstract":"","PeriodicalId":9129,"journal":{"name":"BMC Gastroenterology","volume":"25 1","pages":"682"},"PeriodicalIF":2.5,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12482447/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145190985","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of pathological features of patients with antibody-negative and positive primary biliary cholangitis.","authors":"Hong-Li Liu, Xing Liu, Yi-Fan Hu, Xi-Xuan Wang, Yu Zhang, Li Wang, Sha-Sha Li, Yi-Jun Bao, Si-Wei Zheng, Qing-Fang Xiong, Yan-Dan Zhong, Du-Xian Liu, Ping Huang, Xiao-Ning Feng, Wen-Quan Zeng, Cai-Yun Zhang, Kai Zhang, Yong-Feng Yang","doi":"10.1186/s12876-025-04280-5","DOIUrl":"10.1186/s12876-025-04280-5","url":null,"abstract":"<p><strong>Objective: </strong>To examine the differences and similarities among primary biliary cholangitis (PBC) with positive and negative expression of autoantibodies (anti-mitochondrial antibodies AMA and AMA-M2, antinuclear antibodies anti-gp210, and anti-sp100).</p><p><strong>Methods: </strong>Clinical and pathological data of 85 PBC in patients who underwent liver puncture biopsy were retrospectively collected from January 2016 to September 2018 at the Second Hospital of Nanjing. The differences in clinical and pathological indexes of PBC between autoantibody negative and positive groups were analyzed by SPSS 25.0, and the patients' previous autoantibody indexes were collected for follow-up.</p><p><strong>Results: </strong>The average age of 85 PBC patients was (52.2 ± 9.2) years old, including 15 males (17.6%) and 70 females (82.4%), with a male-to-female ratio of 1:4.7. Fifty-nine autoantibody-positive cases and 26 autoantibody-negative cases were 50 (84.7%) AMA positive, 51 (86.4%) AMA-M2 positive, 21 (35.6%) anti-gp210 positive, and 15 (25.4%) anti-sp100 positive. The distribution of CK7-positive hepatocytes and the degree of bile duct injury in the portal area of PBC patients in the antibody-negative group were lower than those in the antibody-positive group (P < 0.05). There was no significant difference in the distribution of interface inflammation, plasma cell grade, ductular reaction, and fibrosis between the two groups. When the autoimmune antibodies were reexamined at 2 months-7 years (median time 1 year), AMA, AMA-M2, anti-gp210, and anti-sp100 were still negative in 16 antibody-negative patients.</p><p><strong>Conclusions: </strong>The pathological symptoms and diagnostic patterns of autoantibody-negative and positive PBC were generally comparable. In this study, the pathological manifestations of antibody-negative PBC were similar to those of antibody-positive PBC, but the lymphocyte aggregation in antibody-negative PBC was more severe than that in antibody-positive PBC, while the degree of bile duct injury and CK7-positive hepatocytes were milder than that in antibody-positive PBC, suggesting that the overall pathological changes of antibody-negative PBC were slightly milder than those of antibody-positive PBC.</p>","PeriodicalId":9129,"journal":{"name":"BMC Gastroenterology","volume":"25 1","pages":"667"},"PeriodicalIF":2.5,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12482664/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145191043","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of cholecystectomy on Metabolic dysfunction-Associated Steatotic Liver Disease and metabolic syndrome: a 6-month prospective cohort study.","authors":"Mohammad Hadi Bahri, Susan Navabian, Homa Akbari, Javad Zebarjadi Bagherpour, Ramin Bozorgmehr, Mahdi Mohammaditabar","doi":"10.1186/s12876-025-04269-0","DOIUrl":"10.1186/s12876-025-04269-0","url":null,"abstract":"<p><strong>Background: </strong>Cholecystectomy, a common surgery, may cause metabolic changes linked to bile acid metabolism. Early studies suggest a possible link between cholecystectomy and Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD) and metabolic syndrome, but findings are inconclusive. This 6-month study aimed to assess how elective cholecystectomy affects metabolic syndrome development and MASLD progression in a Middle Eastern population.</p><p><strong>Methods: </strong>Participants included 51 patients undergoing elective cholecystectomy and 49 matched controls. MASLD grade and metabolic syndrome status were assessed at baseline and six months post-intervention using ultrasonography and standard clinical criteria.</p><p><strong>Results: </strong>A total of 100 patients were included in the present study, with 51 assigned to the cholecystectomy group and 49 to the control group. Over a six-month follow-up period, individuals in the cholecystectomy group experienced a significant decrease in body mass index (BMI) (p < 0.05) and fasting blood sugar (FBS) levels (p < 0.05). However, this group also exhibited a significant increase in systolic blood pressure (SBP) and diastolic blood pressure (DBP) (p < 0.05). In contrast, the control group showed significant improvements in FBS (p < 0.05) and HDL cholesterol levels (p < 0.05). Logistic regression analysis revealed that undergoing cholecystectomy was linked to a higher likelihood of developing metabolic syndrome (OR = 9.63, p < 0.05).</p><p><strong>Conclusions: </strong>Our findings highlight the potential metabolic implications of cholecystectomy. Cholecystectomy was associated with reduced BMI and improved fasting glucose but significantly increased blood pressure over 6 months. Highlighting the need for careful metabolic monitoring post-surgery.</p>","PeriodicalId":9129,"journal":{"name":"BMC Gastroenterology","volume":"25 1","pages":"671"},"PeriodicalIF":2.5,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12482017/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145191058","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment of patients with hyperthyroidism and liver failure: a retrospective cohort study.","authors":"Zhanyi Li, Xiangyong Li, Xiaoqiong Shao, Qinyao Xu, Yuankai Wu, Yu Liu","doi":"10.1186/s12876-025-04286-z","DOIUrl":"10.1186/s12876-025-04286-z","url":null,"abstract":"<p><strong>Background: </strong>Hyperthyroidism complicated by liver failure is associated with high mortality, and the optimal treatment strategy remains unclear. We aimed to compare the clinical characteristics of patients who received different treatments for hyperthyroidism and liver failure.</p><p><strong>Methods: </strong>This retrospective cohort study included 137 patients diagnosed with hyperthyroidism and Liver failure between January 2013 and December 2022. The patients were treated with methimazole (MMI) plus artificial liver support system (ALSS), radioactive iodine (¹³¹I) plus ALSS, or MMI alone for 24 weeks. Liver and thyroid function were monitored to determine treatment efficacy and potential complications.</p><p><strong>Results: </strong>After propensity score matching, no significant differences in treatment efficacy were observed between MMI plus ALSS and MMI alone at discharge (P = 0.425), 12 weeks (P = 0.104), or 24 weeks (P = 0.104). There were also no significant differences in treatment efficacy between ¹³¹I plus ALSS and MMI alone. However, hospital stays were shorter in the MMI and ¹³¹I plus ALSS groups than in the MMI alone group (P = 0.014 and P = 0.010, respectively). The incidence of adverse events did not differ significantly between the groups.</p><p><strong>Conclusions: </strong>Our results suggest that ¹³¹I plus ALSS, MMI plus ALSS or MMI are effective in treating hyperthyroidism and liver failure, and that the addition of ALSS reduces recovery times. Therefore, clinicians can select any of these treatment options based on specific patient characteristics.</p>","PeriodicalId":9129,"journal":{"name":"BMC Gastroenterology","volume":"25 1","pages":"676"},"PeriodicalIF":2.5,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12482396/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145191182","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative efficacy and safety of endovascular intervention versus conservative therapy in Budd-Chiari syndrome: a retrospective cohort study.","authors":"Xiaojun Wang, Longhua Fan","doi":"10.1186/s12876-025-04290-3","DOIUrl":"10.1186/s12876-025-04290-3","url":null,"abstract":"<p><strong>Objective: </strong>This retrospective cohort study aims to compare the efficacy and safety of endovascular intervention with conservative therapy in patients with Budd-Chiari syndrome (BCS).</p><p><strong>Methods and materials: </strong>A total of 188 patients diagnosed with BCS were divided into endovasular intervention (n = 108) and conservative therapy (n = 80) groups. Primary endpoints were clinical success and overall survival (OS) at 24 months. Clinical success was defined as a ≥ 50% reduction in ascites and the absence of variceal bleeding within 6 months. Secondary outcomes included improvement in liver function and incidence of major complications.</p><p><strong>Results: </strong>The clinical success rate was significantly higher in the endovasular intervention group compared to the conservative therapy group [77.0% vs. 41.3%; p< 0.001; relative risk (RR) = 1.86; 95% confidence interval (CI): 1.41-2.45]. The 24-month OS was superior in the endovasular intervention group [95.4%vs. 85.0%; hazard ratio (HR) = 0.30, 95% CI: 0.09-0.80; p= 0.02]. Patients receiving endovascular intervention demonstrated greater improvement in liver function. No significant difference was found in the incidence of major complications between the two groups (1.6% vs. 2.5%; p= 0.64).</p><p><strong>Conclusion: </strong>Endovascular intervention is associated with significantly higher clinical success rate and a 70% reduction in 2-year mortality compared to conservative therapy, without an increase in major complications. These results support the use of endovascular intervention as a preferred first-line treatment in appropriately selected patients with BCS.</p><p><strong>Practice implications: </strong>The clinical advantages of endovascular intervention underscore the need for standardized treatment protocols in BCS. Early implementation of interventional strategies by hepatologists and radiologists may enhance both OS and quality of life for patients.</p>","PeriodicalId":9129,"journal":{"name":"BMC Gastroenterology","volume":"25 1","pages":"680"},"PeriodicalIF":2.5,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12482552/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145191031","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Burden and determinants of upper gastrointestinal bleeding in cirrhotic patients: evidence from Sub-Saharan Africa, 2024.","authors":"Bekele Taye, Yihealem Yabebal Ayele, Dessalegne Nigatu Achenef, Gedefaw Abeje, Agerye Kassa Yirdaw","doi":"10.1186/s12876-025-04298-9","DOIUrl":"10.1186/s12876-025-04298-9","url":null,"abstract":"<p><strong>Introduction: </strong>Upper gastrointestinal bleeding (UGIB) is a serious and life-threatening complication of liver cirrhosis, contributing a notable percentage to emergency admissions, morbidity, and mortality. There is limited evidence regarding UGIB prevalence and determinants among cirrhotic patients in Ethiopia, particularly in the study setting.</p><p><strong>Objective: </strong>To determine the magnitude of UGIB and its associated factors in cirrhotic patients visiting public hospitals in Northwest Ethiopia, 2024.</p><p><strong>Methods: </strong>A facility-based cross-sectional study was performed in 256 cirrhotic patients from November 2024 to January 2025. Participants were enrolled through consecutive sampling. Data were gathered with the help of a structured checklist, entered into Epi Data version 3.1, and analyzed using SPSS version 27.0. Descriptive statistics presented patient characteristics. Bivariate and multivariate logistic regression analyses were performed to determine factors related to UGIB. Adjusted odds ratios (AOR) with 95% confidence intervals (CI) were presented, and the statistical significance level was p < 0.05.</p><p><strong>Results: </strong>UGIB prevalence was 46.1%. Significantly associated factors were illness duration > 24 months (AOR = 2.42; 95% CI: 1.34-4.35), platelet count 50,000-100,000/µL (AOR = 1.90; 95% CI: 1.23-3.61), platelet count < 50,000/µL (AOR = 5.27; 95% CI: 2.63-10.56), and absence of prior endoscopy (AOR = 3.62; 95% CI: 1.95-6.69).</p><p><strong>Conclusion: </strong>UGIB prevalence was high in this cirrhotic population, primarily due to esophageal varices. Long duration of the disease, thrombocytopenia, and absence of endoscopic screening were significant risk factors identified. These findings underscore the importance of early endoscopic screening, thrombocytopenia monitoring, and the expansion of preventive services to reduce UGIB-related complications in cirrhotic patients.</p>","PeriodicalId":9129,"journal":{"name":"BMC Gastroenterology","volume":"25 1","pages":"679"},"PeriodicalIF":2.5,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12481966/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145191041","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neoadjuvant chemotherapy strategies for optimizing safety and efficacy in elderly patients with locally advanced gastric cancer.","authors":"Yoshihiko Kakiuchi, Shinji Kuroda, Shunya Hanzawa, Nobuhiko Kanaya, Hajime Kashima, Satoru Kikuchi, Kunitoshi Shigeyasu, Shunsuke Kagawa, Toshiyoshi Fujiwara","doi":"10.1186/s12876-025-04281-4","DOIUrl":"10.1186/s12876-025-04281-4","url":null,"abstract":"<p><strong>Background: </strong>The completion rate of adjuvant chemotherapy for gastric cancer (GC) is suboptimal, particularly in elderly patients. While neoadjuvant chemotherapy (NAC) for locally advanced GC has shown promise, data on elderly patients remain limited. Given the considerable physical burden of NAC, optimizing its administration is crucial. This study evaluates the safety and efficacy of a modified approach for elderly patients.</p><p><strong>Methods: </strong>A retrospective analysis was conducted on 38 patients with cStage II/III GC who received NAC between November 2015 and December 2023. Additionally, 25 patients aged ≥ 75 years with cStage III who underwent upfront surgery during the same period were analyzed.</p><p><strong>Results: </strong>The NAC group was divided into non-elderly (< 75 years, n = 27) and elderly (≥ 75 years, n = 11) groups. The elderly group had poorer ECOG-PS (p = 0.016). While all non-elderly patients completed ≤ 3 cycles, more elderly patients underwent 4 cycles (p = 0.0047). However, per-cycles of S-1 (p = 0.0003) and oxaliplatin (p = 0.0018) were lower in the elderly group. Importantly, adverse events and treatment efficacy were comparable between groups. Among patients aged ≥ 75 years, the upfront surgery group had poorer ECOG-PS (p = 0.017) and underwent more frequent distal gastrectomy (p = 0.014).</p><p><strong>Conclusions: </strong>NAC can be safely administered to elderly patients by increasing cycles while reducing per-cycle dosage. It may also serve as a viable alternative to upfront surgery.</p>","PeriodicalId":9129,"journal":{"name":"BMC Gastroenterology","volume":"25 1","pages":"670"},"PeriodicalIF":2.5,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12482018/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145191061","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic value of preoperative serum tumor markers in gallbladder cancer.","authors":"Qianhui Duan, Jie Zhong, Yinghui Song, Sicheng Zhang, Weimin Yi, Chuang Peng, Sulai Liu, Jianping Wu, Lianhong Zou","doi":"10.1186/s12876-025-04270-7","DOIUrl":"10.1186/s12876-025-04270-7","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the clinical factors related to poor prognosis of gallbladder cancer (GBC) patients, and to develop a prognostic model which may provide the guidance for clinical decision-making.</p><p><strong>Methods: </strong>The clinical and pathological data of 136 patients with GBC admitted and treated in the Hunan Provincial People's Hospital from January 2018 to July 2023 were retrospectively analyzed. All patients were followed up periodically by telephone, with the final follow-up on July 15, 2024. The Kaplan-Meier method was employed for univariate survival analysis. The log-rank test was utilized to assess differences in survival curves. A Cox regression model was applied for multivariate analysis to identify independent prognostic factors for GBC. Independent prognostic factors identified through Cox modeling were integrated into a nomogram. Finally, receiver operating characteristic (ROC) curves and calibration curves were plotted for 1-, 2-, and 3-year survival predictions.</p><p><strong>Results: </strong>GBC patients were predominantly female and elderly. GBC patients with diabetes, jaundice and Child-Pugh B/C classification of liver function had poorer overall survival (OS) outcomes. Elevated serum tumor biomarkers CA19-9, CA125, CEA, CA724 and CYFRA21-1 were associated with unfavorable OS in GBC patients. Additionally, the differentiation grade, Lymphovascular invasion (LVI), perineural invasion (PNI), clinical staging and TNM staging were also related to the OS of GBC patients. For GBC patients who underwent surgical treatment, OS was significantly improved, with the most notable improvement observed in those who received radical surgery. GBC patients treated with chemotherapy-based drug treatment experienced an improvement in OS. Multivariate Cox regression analysis revealed that diabetes, elevated CA125, and advanced TNM stage were independent risk factors for GBC prognosis, while chemo-immunotherapy/targeted therapy was an independent protective factor.</p><p><strong>Conclusion: </strong>Diabetes, elevated CA125 levels, TNM stage, and chemo-immunotherapy/targeted therapy are independent prognostic factors for GBC patients, which could be used to develop a nomogram model and contribute to provide the guidance for clinical treatment.</p>","PeriodicalId":9129,"journal":{"name":"BMC Gastroenterology","volume":"25 1","pages":"678"},"PeriodicalIF":2.5,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12482541/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145191141","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}